Of particular importance, miRNAs involved in the regulation of ER-RTK crosstalk may serve as leading candidates for the development of novel miRNA-based breast cancer therapies targeting multiple oncogenic pathways. The gene discussed is ESR1; the disease is breast carcinoma.